19:18 , Apr 13, 2018 |  BC Week In Review  |  Company News

Novo Nordisk licenses sickle cell candidate from EpiDestiny

EpiDestiny Inc. (Solon, Ohio) granted Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) exclusive, worldwide rights to EPI01 to treat sickle cell disease (SCD) and beta-thalassemia. EpiDestiny is eligible for more than $400 million, comprising a $12 million...
22:20 , Apr 5, 2018 |  BC Extra  |  Company News

Novo in deal for EpiDestiny's hematology candidate

EpiDestiny Inc. (Solon, Ohio) granted Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) exclusive, worldwide rights to EPI01 to treat sickle cell disease (SCD) and beta-thalassemia. EpiDestiny is eligible for more than $400 million, comprising a $12 million...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
16:48 , Oct 17, 2017 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Thalassemia Cell and human embryo studies suggest base editing of β-globin mutations could help treat β-thalassemia. In fibroblast cells from a β-thalassemia patient harboring an A28G SNP in β-globin, a base editor system comprising an...
20:41 , Sep 29, 2017 |  BC Extra  |  Preclinical News

Researchers use base editing to correct beta-thalassemia mutation

In a paper published in Protein & Cell, researchers at Sun Yat-sen University and colleagues used a gene editing technique called base editing to correct a single point mutation in human cells and embryos that...
22:39 , Sep 14, 2017 |  BC Extra  |  Preclinical News

Intratumor bacteria could confer resistance to gemcitabine

In a paper published in Science, researchers at the Weizmann Institute of Science and colleagues showed that intratumor bacteria can metabolize the chemotherapeutic drug gemcitabine, inducing tumor resistance to the therapy. The researchers analyzed 27 bacterial...
23:04 , Jun 29, 2017 |  BC Extra  |  Preclinical News

Paper describes inducible CRISPR

In a Nature Communications study published Wednesday, Harvard professor David Liu and colleagues described a new method to control activation of gene editing technologies with small molecule-inducible guide RNAs. The team designed the inducible guides...
23:03 , Jun 29, 2017 |  BC Extra  |  Preclinical News

Paper describes inducible CRISPR

In a Nature Communications study published Wednesday, Harvard professor David Liu and colleagues described a new method to control activation of gene editing technologies with small molecule-inducible guide RNAs. The team designed the inducible guides...
18:45 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

CRISPR to the point

As improvements to CRISPR-based gene editing continue apace, a Harvard University leader in the space has produced an updated version of a technology he described only a year ago for accurately generating point mutations without...
16:27 , Jun 27, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms; drug delivery

TECHNOLOGY: Gene therapy; other A cytidine deaminase base editor delivered in ribonucleoprotein (RNP) form could be used to develop high-specificity gene editing therapies capable of correcting single-point mutations. The cytidine deaminase base editor includes two proteins:...